Eurocine Vaccines expect to present the results from the ongoing PhaseI/II study with the the first product candidate Immunose™ FLU.
Category: Uncategorized
Eurocine Vaccines will be in place to meet vaccine professionals from industry, academia, non-profit organizations and government to discuss challenges and successes but also present the latest news about our technology plattform Endocine™ and the latest results from the study made with product candidate Immunose™ FLU. Date and time for the presentation will be announced